血细胞参数在小细胞肺癌治疗中的预测作用

国际肿瘤学杂志››2019,Vol. 46››Issue (8): 496-499.doi:10.3760/cma.j.issn.1673-422X.2019.08.011

血细胞参数在小细胞肺癌治疗中的预测作用

沈夏波^1，2王伟²潘跃银^1，2

¹安徽医科大学附属安徽省立医院肿瘤内科，合肥 230001；²中国科学技术大学附属第一医院肿瘤内科，合肥 230001

收稿日期:2019-06-14修回日期:2019-07-09出版日期:2019-08-08发布日期:2019-10-31
通讯作者:王伟; 潘跃银 E-mail:docweiwang@fsyy.ustc.edu.cn; panyueyin@ustc.edu.cn
基金资助:

安徽省自然科学基金（1908085MH260）；安徽省科技攻关项目（1704a0802148）

Prognostic significance of blood cell parameters in the treatment of small cell lung cancer

Shen Xiabo^1,2, Wang Wei², Pan Yueyin^1,2

¹Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China;²Department of Medical Oncology, First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China

Received:2019-06-14Revised:2019-07-09Online:2019-08-08Published:2019-10-31
Contact:Wang Wei E-mail:docweiwang@fsyy.ustc.edu.cn; panyueyin@ustc.edu.cn
Supported by:

Natural Science Foundation of Anhui Province of China (1908085MH260); Key Research and Development Project from Science and Technology Department of Anhui Province of China (1704a0802148)

摘要/Abstract

摘要：小细胞肺癌是发生于肺部的一种特殊类型的神经内分泌肿瘤，其治疗效果不佳，易耐药、复发和远处转移。因此，探寻易获得的预测参数对于临床治疗有重要意义。现血细胞参数中部分指标在非小细胞肺癌、乳腺癌、胃癌、结直肠癌等恶性肿瘤中有广泛的研究。深入了解血细胞参数在小细胞肺癌中的预测作用及其可能的机制，对预测小细胞肺癌疗效和预后有重要价值。

关键词:小细胞肺癌,治疗效果,预测,血细胞参数

Abstract:Small cell lung cancer is a special type of neuroendocrine tumor in the lungs, which has a poor therapeutic effect, and a short time for resistance to relapse, recurrence and distant metastasis. Therefore, searching for readily available predictive parameters is important for clinical treatment strategy. Some indicators of blood cell parameters have been extensively studied in malignant tumors such as non-small cell lung cancer, breast cancer, gastric cancer and colorectal cancer. Indepth understanding of the role of blood cell parameters in small cell lung cancer and its possible mechanisms are of great value in predicting the curative effect and prognosis of small cell lung cancer.

Key words:Small cell lung carcinoma,Treatment outcome,Forecasting,Blood cell parameters

沈夏波, 王伟, 潘跃银. 血细胞参数在小细胞肺癌治疗中的预测作用[J]. 国际肿瘤学杂志, 2019, 46(8): 496-499.

Shen Xiabo, Wang Wei, Pan Yueyin. Prognostic significance of blood cell parameters in the treatment of small cell lung cancer[J]. Journal of International Oncology, 2019, 46(8): 496-499.

参考文献

［1］ Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: small cell lung cancer, version 2.2018［J］. J Natl Compr Canc Netw, 2018, 16(10): 1171-1182. DOI: 10.6004/jnccn.2018.0079. ［2］ Hong J, Chen X, Gao W, et al. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab［J］. Cancer Manag Res, 2019, 11: 3371-3379. DOI: 10.2147/cmar.s187233. ［3］ Xue W, Tan P, Xu H, et al. Impact of the preoperative prognostic nutritional index on survival outcomes in upper tract urothelial carcinomas［J］. Cancer Med, 2019, 8(6): 2971-2978. DOI: 10.1002/cam4.2161. ［4］ Inamoto S, Kawada K, Okamura R, et al. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study［J］. Int J Colorectal Dis, 2019, 34(7): 1303-1315. DOI: 10.1007/s00384-019-03316-z. ［5］ Wen Q, Meng X, Xie P, et al. Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy［J］. Oncotarget, 2017, 8(46): 81405-81418. DOI: 10.18632/oncotarget.19073. ［6］ Suzuki R, Lin SH, Wei X, et al. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer［J］. Radiother Oncol, 2018, 126(3): 499-505. DOI: 10.1016/j.radonc.2017.12.030. ［7］ Zheng Y, Wang L, Zhao W, et al. Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation［J］. Strahlenther Onkol, 2018, 194(12): 1152-1162. DOI: 10.1007/s00066-018-1362-7. ［8］ Wang X, Jiang R, Li K. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer［J］. Cell Biochem Biophys, 2014, 69(3): 633-640. DOI: 10.1007/s12013-014-9845-3. ［9］ Bernhardt D, Aufderstrasse S, Konig L, et al. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy［J］. Cancer Manag Res, 2018, 10: 6563-6569. DOI: 10.2147/cmar.s180990. ［10］ Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer［J］. Br J Cancer, 2014, 111(3): 452-460. DOI: 10.1038/bjc.2014.317. ［11］ Go SI, Kim RB, Song HN, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer［J］. Med Oncol, 2014, 31(12): 323. DOI: 10.1007/s12032-014-0323-y. ［12］ Cao S, Jin S, Shen J, et al. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients［J］. Oncotarget, 2017, 8(5): 8657-8669. DOI: 10.18632/oncotarget.14395. ［13］ Rades D, Kaesmann L, Janssen S, et al. A new score for estimating survival after definitive radiochemotherapy of limited disease small cell lung cancers［J］. Lung, 2016, 194(4): 625-629. DOI: 10.1007/s00408-016-9886-z. ［14］ Inomata M, Hayashi R, Tokui K, et al. Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapy［J］. Tumori, 2014, 100(5): 507-511. DOI: 10.1700/1660.18164. ［15］ Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients［J］. Nihon Geka Gakkai Zasshi, 1984, 85(9): 1001-1005. ［16］ Hong S, Zhou T, Fang W, et al. The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients［J］. Tumour Biol, 2015, 36(5): 3389-3397. DOI: 10.1007/s13277-014-2973-y. ［17］ Minami S, Ogata Y, Ihara S, et al. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer［J］. Lung Cancer (Auckl), 2017, 8: 249-257. DOI: 10.2147/lctt.s142880. ［18］ Go SI, Jeon H, Park SW, et al. Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer［J］. Thorac Cancer, 2018, 9(11): 1483-1491. DOI: 10.1111/17597714.12862. ［19］ Jin S, Cao S, Xu S, et al. Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy［J］. Clin Respir J, 2018, 12(9): 2433-2440. DOI: 10.1111/crj.12925. ［20］ Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review［J］. BMC Cancer, 2013, 13: 158. DOI: 10.1186/1471-2407-13-158. ［21］ He X, Zhou T, Yang Y, et al. Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer［J］. Clin Lung Cancer, 2015, 16(6): e165-e171. DOI: 10.1016/j.cllc.2015.03.005. ［22］ Kim EY, Kim N, Kim YS, et al. Prognostic significance of modified advanced lung cancer inflammation index (ALI) in patients with small cell lung cancer_ comparison with original ALI［J］. PLoS One, 2016, 11(10): e0164056. DOI: 10.1371/journal.pone.0164056. ［23］ Mirili C, Guney IB, Paydas S, et al. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC)［J］. Int J Clin Oncol, 2019, 24(2): 168-178. DOI: 10.1007/s10147-018-1338-8. ［24］ Tokunaga R, Nakagawa S, Miyamoto Y, et al. The impact of preoperative anaemia and anaemic subtype on patient outcome in colorectal cancer［J］. Colorectal Dis, 2019, 21(1): 100-109. DOI: 10.1111/codi.14425. ［25］ Passiglia F, Galvano A, Castiglia M, et al. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients［J］. Ther Adv Med Oncol, 2019, 11: 1758835919839928. DOI: 10.1177/1758835919839928. ［26］ Suh KJ, Kim SH, Kim YJ, et al. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody［J］. Cancer Immunol Immunother, 2018, 67(3): 459-470. DOI: 10.1007/s00262-017-2092-x.

[1]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[2]	刘利, 朱思齐, 孙梦颖, 何敬东.PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[3]	王雅倩, 杜逸玮, 王兴, 贾军梅.小细胞肺癌免疫治疗预后预测指标研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 179-182.
[4]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻.胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[5]	黄锐, 张允清.安罗替尼单药在PS评分差的广泛期小细胞肺癌二线治疗中的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(12): 705-710.
[6]	焦盼盼, 薛丽娟, 詹娟.免疫检查点抑制剂相关不良反应的危险因素与预测因素[J]. 国际肿瘤学杂志, 2023, 50(12): 739-744.
[7]	陈郁, 许华, 刘海, 陈士新.基于CT影像学特征的恶性肺纯磨玻璃结节患者病理分型预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(11): 655-660.
[8]	林榕生, 吴楚海, 郭颖梅, 王涛, 陈荣斌, 刘少琴, 甘兵.特瑞普利单抗联合贝伐珠单抗二线以上治疗MSI-H型转移性结直肠癌的疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(2): 100-105.
[9]	朱一硕, 崔玉洁, 刘崎, 李军, 范月超.脑胶质瘤患者术后早期复发危险因素分析及预测模型构建[J]. 国际肿瘤学杂志, 2022, 49(2): 79-83.
[10]	陶洁, 吴梅, 张琰.安罗替尼治疗二线失败后老年小细胞肺癌患者的疗效及影响因素分析[J]. 国际肿瘤学杂志, 2022, 49(1): 39-44.
[11]	张红娥, 周清华, 刘洁薇, 代爽, 周洁.预防性全脑照射引起小细胞肺癌患者脑损伤的研究进展[J]. 国际肿瘤学杂志, 2021, 48(9): 568-571.
[12]	林雅茹, 马晓林, 孙磊, 王桂春, 张琳, 路中.安罗替尼致小细胞肺癌患者脑梗死二例[J]. 国际肿瘤学杂志, 2021, 48(9): 575-576.
[13]	武志, 杨光, 李琳, 张强.广泛期小细胞肺癌胸部放疗研究进展[J]. 国际肿瘤学杂志, 2021, 48(4): 231-234.
[14]	张孟伟, 卢红.应用安罗替尼治疗小细胞肺癌伴脑转移患者一例[J]. 国际肿瘤学杂志, 2021, 48(2): 125-126.
[15]	曹纯, 何文琪, 晏军.免疫检查点抑制剂在小细胞肺癌治疗中的应用[J]. 国际肿瘤学杂志, 2021, 48(12): 747-750.